In mid-July, several members of the RHU TIPITCH consortium attended #ISTH2026 (International Society on Thrombosis and Haemostasis) in Paris, a leading global conference for research in thrombosis, haemostasis, and bleeding disorders.
Among the highlights, Charlotte Bocquet, a PhD student within the project under the supervision of Prof. Annabelle Dupont, presented a poster on the characterisation of rivaroxaban-associated intracerebral haematomas using an ex vivo model replicating the MISTIE procedure. This work is fully aligned with the objectives of WP2, dedicated to improving minimally invasive haematoma evacuation strategies.
Prof. Annabelle Dupont, co-lead of WP2, also delivered a well-received oral presentation on the identification of the SLC35D3 gene as a novel causative gene in a rare inherited platelet disorder. This multidisciplinary study combined cellular biology, electron microscopy, structural modelling and in silico analyses, with a notable contribution from Mickael Rosa.
TIPITCH’s presence at ISTH perfectly illustrates one of the project’s key strengths: bringing together world-class expertise at the intersection of haematology, neurology, imaging, fundamental research, and therapeutic innovation. We are proud to count among our consortium internationally recognised experts whose work is advancing knowledge far beyond the field of haemorrhagic stroke.
Beyond the scientific presentations, ISTH provided an excellent opportunity to share project advances, discuss findings with international experts, and strengthen links between basic, translational, and clinical research.
Congratulations to all the teams involved, and thank you for your continued commitment to advancing the scientific visibility and impact of TIPITCH.
Spontaneous intracerebral haemorrhages (also known as haemorrhagic strokes) remain among the most severe forms of stroke, with significant consequences for patients and their families.
In response to this challenge, the French Hospital-University Research (RHU) project TIPITCH has, since 2024, brought together a large community of researchers, clinicians and partners to advance research and improve patient care.
The objective: to better understand, better treat and better support patients at every stage of their journey.
A project structured around four key pillars
TIPITCH is built on several complementary work streams, enabling action at different stages of the disease.
1. Limiting haemorrhage progression
In the early hours, one of the major challenges is to prevent the haematoma (bleeding in the brain) from worsening.
Teams are currently developing innovative miniature devices capable of temporarily modulating blood flow to limit the expansion of bleeding.
These technologies are still at an experimental stage but represent a completely new approach in the management of haemorrhagic stroke.
2. Improving haematoma evacuation
In haemorrhagic stroke, removing the haematoma is often necessary to relieve pressure on the brain.
TIPITCH researchers are developing and testing less invasive approaches, combining minimally invasive surgical techniques with clot-dissolving treatments.
A key aspect is a better understanding of clot composition, enabling treatments to be adapted to each patient.
This approach paves the way for more personalised medicine, particularly for patients on anticoagulants or at increased bleeding risk.
3. Better understanding secondary brain injury
The impact of stroke extends beyond the bleeding itself: surrounding brain tissue is also affected (inflammation, oedema, etc.).
TIPITCH is developing advanced imaging tools (MRI, PET imaging) to:
- better visualise these processes
- understand their consequences
- identify new therapeutic targets
A clinical trial is also underway to test a drug designed to modulate inflammation and limit secondary damage.
4. Placing patients at the heart of research
This is a defining feature of the project. 
- participation in care pathway design
- contribution to research
- improvement of information and support
The goal is clear: to conduct research with patients, not just for them.
A strong collective dynamic
Two years after its launch, TIPITCH is demonstrating a highly positive momentum. At the most recent annual meeting, teams highlighted:
- strong collaboration between centres
- innovation at the core of the project
- increasing programme maturity
Interactions between researchers, clinicians and patients are helping to build a genuine collaborative research ecosystem, focused on delivering practical solutions.
Why does this research matter for patients?
Today, treatment options for haemorrhagic stroke remain limited.
TIPITCH research aims to:
- improve acute-phase treatment
- reduce long-term disability
- adapt management to individual patient profiles
- enhance long-term patient support
Although progress takes time, these advances are essential to achieving more effective and personalised treatments in the future.
TIPITCH represents one of France’s major research efforts in the field of intracerebral haemorrhage.
Thanks to a comprehensive approach — from emergency care to post-stroke follow-up, combining technological innovation and patient involvement — it is opening up concrete perspectives for improving patient management.
Monday,11th , the TIPITCH community gathered at Lille University Hospital for its annual meeting. A day rich in discussions, marked by strong engagement from the consortium and a collective commitment from across France.
A heartfelt thank you to all participants for your presence and active involvement.
Congratulations to the principal investigators for the clarity of their presentations and the outstanding scientific work shared throughout the day.
Warm thanks to the members of the Scientific Advisory Board (Prof. Lauren Sansing – Yale School of Medicine, Prof. Simon De Meyer – KU Leuven and Prof. Rustam Al-Shahi Salman – The University of Edinburgh) for their valuable feedback, insightful advice and great benevolence, which strongly contribute to the project’s momentum.
We also thank the representatives of the ANR (French National Research Agency) for their long‑term support and continued guidance.
The Wooclap interactive session launched at the beginning of the meeting captured real‑time feedback from the consortium. Your contributions highlighted strong key words — collaboration, enthusiasm, innovation, excellence. The innovation dynamic clearly emerged as one of the project’s defining features, alongside methodological robustness, strong consortium structuring and the richness of exchanges.
Once again, this meeting illustrates the strength of the TIPITCH collective and the shared energy driving research forward, in the service of patients.
Thank you all for your continued commitment
A Prestigious Recognition for a TIPITCH Project Member
The RHU TIPITCH project extends its warmest congratulations to Prof. Aymeric Rouchaud (Limoges University Hospital, CNRS), leader of Work Package 1, on his appointment to the Institut Universitaire de France (IUF) in the Innovation category for the 2026 cohort.
This national distinction recognises an outstanding scientific career at the crossroads of interventional neuroradiology, translational research and technological innovation, all dedicated to improving patient care.
Within TIPITCH, Prof. Rouchaud leads a key work package focused on intervening during the earliest stages of intracerebral haemorrhage to limit haematoma expansion, a critical challenge in improving patient outcomes.
As he himself emphasises, this recognition is first and foremost a collective achievement, reflecting the commitment of all the teams involved — researchers, engineers, clinicians and early-career scientists — who work every day to advance research and innovation.
Congratulations to Prof. Aymeric Rouchaud on this well-deserved distinction, which also highlights the pivotal role of French research in driving the development of innovative healthcare solutions.
The RHU TIPITCH project is proud to highlight the work of Dr Nourou Dine A. Bankole, PhD, conducted under the supervision of Prof. Grégoire Boulouis, Prof. Marco Pasi and Dr Ilyess Zemmoura (Tours University Hospital).
Their article, recently published in the journal Neurochirurgie, presents an innovative technical note on optimising the management of intracerebral haematomas using an ultrasound-guided minimally invasive technique (HUG-MIS).
This work makes a valuable contribution by describing an approach that could improve the safety, precision and effectiveness of haematoma evacuation, a key challenge in the management of patients with haemorrhagic stroke.
Congratulations to Nourou Dine A. Bankole and his supervisors on this publication, which perfectly illustrates the innovation-driven momentum of TIPITCH and the commitment of the teams at Tours University Hospital, a key partner of the project.
Read the article: https://lnkd.in/eA2Bfav2
Intracerebral hemorrhage (ICH) holds a particularly prominent place in this year’s programme, with dedicated sessions, clinical trials, and innovative approaches spanning imaging, pathophysiology, and brain repair.
This is a crucial recognition for a condition that still too often lacks disease‑specific therapeutic solutions.
The TIPITCH RHU is proud to actively contribute to this momentum, with numerous presentations delivered by members of the consortium:
🔹 Prof. Charlotte Cordonnier (CHU de Lille)
• ESOC TV – Large Clinical Trials: implications for clinical practice
• Microcirculatory dysfunction in intracerebral hemorrhage
🔹 Dr Laurent Puy (Lille University Hospital)
• Can we stimulate haematoma clearance and repair mechanisms after ICH?
🔹 Dr Quentin Beaufort (PhD, Tours University Hospital)
• Non‑invasive exclusion of arteriovenous shunts in ICH using MRI arterial spin labelling
🔹 Prof. Marco Pasi (CHRU de Tours)
• Clinical relevance of cerebral amyloid angiopathy in acute stroke reperfusion therapies
🔹 Dr Valentin Amar (PhD, Tours University Hospital)
• Poster – Cognitive and neuroimaging profile of sporadic cerebral amyloid angiopathy patients with phosphorylated TAU positivity
Ahead of the main congress, the ICH Academy Meeting will take place on May 5, an international scientific event dedicated to ICH research, featuring contributions from Dr Valentin Amar, Dr Maxime Baudouin, and Dr Quentin Beaufort, PhD candidates within the TIPITCH project.
Thank you to the European Stroke Organisation for the prominent place given to ICH at ESOC 2026, and congratulations to all clinician‑scientists committed to advancing research in this still underexplored field.
Inauguration of the 7‑Tesla MRI at Lille University Hospital: a major step forward for TIPITCH
On 28 April, Lille University Hospital (CHU de Lille), lead institution of the RHU TIPITCH project, inaugurated its 7‑Tesla MRI scanner—an exceptional piece of equipment opening up unprecedented opportunities for clinical research in neuroscience and neurovascular diseases.
This ultra‑high‑resolution imaging technology represents a major strategic asset for the TIPITCH project – Transforming the prognosis of haemorrhagic stroke.
A key lever to better understand haemorrhagic stroke
Within TIPITCH, the 7T MRI will be used to:
🔹 Identify new imaging biomarkers of peri‑haematomal oedema following intracerebral haemorrhage
🔹 Improve the identification of patients at risk of severe disease progression
🔹 Refine predictions of functional outcome, a central challenge for personalised patient care
The ambition: to enhance anticipation and clinical decision‑making through ultra‑high‑precision imaging.
- Prof Grégory Kuchcinski
- Dr Renaud Lopes
What’s next?
First TIPITCH patient inclusions: before summer 2026
This inauguration fully illustrates the CHU de Lille’s ability to bring together cutting‑edge infrastructure, clinical excellence and translational research, all in the service of patients affected by haemorrhagic stroke.
To learn more about the 7‑Tesla MRI at Lille University Hospital: ARIANES : mise en réseaux des IRM 3 Tesla
Regional victory for Guillaume RENEDO: heading to the national final!
Double distinction:
➡️ First Prize – Jury Award
➡️ Audience Award
Thanks to this outstanding performance, Guillaume will represent Nouvelle‑Aquitaine at the national final, which will take place in Lille on 28 May 2026.
A demanding PhD topic, explained with clarity and conviction
Among 18 PhD candidates from higher education institutions across the region, Guillaume stood out for the quality, pedagogy and accessibility of his presentation, focusing on his PhD research:
“Numerical simulation of intraparenchymal haemorrhage: from in silico modelling to the development of an innovative endovascular device.”
This work lies at the very heart of the ambitions of the TIPITCH project, combining numerical modelling, technological innovation and clinical challenges related to haemorrhagic stroke.
Onwards to the national final
This qualification marks entry into the final stage of a high‑level science communication competition, where Guillaume will proudly represent his region, his field of research and French translational research on the national stage.
Watch the national final live:
https://lnkd.in/eRtS3pke
The entire TIPITCH community warmly congratulates Guillaume and wishes him every success for the national final in Lille.
Congratulations Guillaume on this inspiring achievement, which perfectly illustrates the commitment and talent of our Pitchous!
On the occasion of World Haemophilia Day, the RHU TIPITCH project would like to highlight a population that is still too often excluded from clinical studies: patients at high haemorrhagic risk.
This includes in particular:
- people living with haemophilia or other genetic coagulation disorders,
- as well as certain patients receiving anticoagulant therapy.
Although these profiles account for around 15% of intracerebral haemorrhages, they have historically been under‑represented in research, due to the complexity and risks involved.
TIPITCH: addressing this challenge head‑on
Within RHU TIPITCH, a dedicated work package (WP2) directly tackles this issue.
Its objective is to better understand haematoma formation in these specific contexts and to safely promote haematoma evacuation in the patients at highest risk.
To achieve this, the teams:
- use blood samples to model haematomas in the laboratory,
- analyse the biological mechanisms specific to these patients,
- and test innovative approaches, with the aim of developing safer and more appropriate treatments.
A major milestone reached
A key step has recently been achieved: the clinical trial arising from this work began on 2 March.
Since its launch, 40 participants have already been included, clearly illustrating the project’s inclusive ambition:
- 1 healthy volunteer
- 10 patients receiving anticoagulant therapy
- 20 patients receiving antiplatelet therapy
- 3 patients with von Willebrand disease
- 6 patients with haemophilia (3 with haemophilia A and 3 with haemophilia B)
These are profiles that have historically been excluded from clinical trials and are now fully integrated into research — marking a tangible step towards truly inclusive medicine.
Also worth (re)discovering
Our video “TIPITCH in 2 minutes”, in which Prof Annabelle Dupont (Lille University Hospital) presents this key module, co‑led with Prof Sophie Susen, and outlines the foundations of this innovative therapeutic strategy.
On this World Haemophilia Day, TIPITCH reaffirms a strong conviction:
research must also — and above all — address the needs of the most vulnerable patients.
The JNLF 2026 officially opened yesterday in Marseille, bringing together the neurological community to discuss major advances in the field.
This afternoon (3:00–4:15 pm), a session dedicated to intracerebral haemorrhage will highlight key clinical and scientific issues central to neurological practice — a topic at the very heart of the RHU TIPITCH project.
Speakers include:
- Prof Marco Pasi (Tours University Hospital)
“The ICH Checklist: new approaches to the management of intracerebral haemorrhage” - Prof Charlotte Cordonnier (Lille University Hospital)
Long‑term complications following intracerebral haemorrhage
Both are members of the TIPITCH project.
These moments of exchange and knowledge sharing are essential for neurology professionals in order to:
➡️ disseminate knowledge,
➡️ compare and discuss clinical practices,
➡️ and collectively improve the care of patients affected by haemorrhagic stroke.
TIPITCH is fully aligned with this dynamic approach, combining clinical research, innovation and knowledge transfer as close as possible to everyday clinical practice.
Wishing everyone a great JNLF 2026!
